Aramark
ARMK
$56.06
+2.34%
ARAMARK is a global provider of food services, facilities management, and uniform and career apparel, operating primarily within the Specialty Business Services industry. The company is a market leader in outsourced services for education, healthcare, sports and entertainment venues, and businesses, distinguishing itself through its scale, long-term client contracts, and integrated service offerings. The current investor narrative centers on a strong post-pandemic recovery in its core client verticals, particularly in sports and entertainment, and its ability to navigate inflationary pressures through pricing power and operational efficiencies, as evidenced by its recent stock price momentum.…
ARMK
Aramark
$56.06
Investment Opinion: Should I buy ARMK Today?
Rating & Thesis: Hold. ARMK presents a high-risk, high-reward proposition where the powerful recovery narrative appears largely priced in after a 45% six-month rally, leaving limited margin of safety against its fundamental weaknesses. The lack of a clear analyst consensus price target further complicates assessing fair value.
Supporting Evidence: The primary valuation metric, the forward PE of 20.2x, is reasonable if the company delivers on its projected $3.88 EPS, as suggested by a PEG ratio of 1.31. The low Price-to-Sales ratio of 0.56x indicates the market is not paying a premium for revenue. However, the extremely thin net margin of 1.76% and elevated debt-to-equity of 1.82 underscore the operational and financial risks that could derail earnings growth. The stock's massive outperformance versus the S&P 500 (36.2% over six months) suggests much of the positive news is already reflected in the price.
Risks & Conditions: The two biggest risks are a failure to achieve forecasted EPS due to margin pressure, and a technical reversal from overbought conditions near the 52-week high. This Hold rating would upgrade to a Buy if the stock consolidates and the forward PE compresses below 17x while the earnings trajectory remains intact, or if gross margins show sustainable expansion above 6%. It would downgrade to a Sell if the stock breaks below key support (e.g., $50) on an earnings miss, or if the debt-to-equity ratio worsens above 2.0. Based on the current data, the stock appears fairly valued to slightly overvalued relative to its risk profile, trading at the high end of its recent range with significant fundamental headwinds.
Sign up to view all
ARMK 12-Month Price Forecast
The AI assessment is neutral on ARMK with medium confidence. While the forward valuation is not excessive and the recovery theme is credible, the stock's parabolic move has likely front-run much of the good news. The key factors are the high financial leverage and thin margins, which create a fragile foundation for the growth priced in at a 20x forward multiple. The stance would upgrade to bullish only on evidence of sustainable margin improvement and de-leveraging, supported by a successful breakout above $55 on high volume. It would turn bearish on a breakdown below $50 accompanied by deteriorating liquidity metrics or a guidance cut.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Aramark's 12-month outlook, with a consensus price target around $72.88 and implied upside of +30.0% versus the current price.
Average Target
$72.88
5 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
5
covering this stock
Price Range
$45 - $73
Analyst target range
Analyst coverage for ARMK is limited, with only 5 analysts providing estimates, which is indicative of a mid-cap stock with less institutional research focus. The consensus estimates point to forward EPS of $3.88 on revenue of $27.28 billion, with a relatively tight range between EPS estimates of $3.82 (low) and $3.94 (high). The lack of explicit price targets, buy/hold/sell ratings, or a target price range in the provided data constitutes insufficient analyst coverage for a full sentiment analysis; this limited coverage can lead to higher volatility and less efficient price discovery, as the stock may be more reactive to company-specific news rather than broad analyst consensus shifts.
Bulls vs Bears: ARMK Investment Factors
The evidence for ARMK presents a classic tension between a compelling recovery narrative and significant fundamental vulnerabilities. The bullish case is driven by powerful technical momentum, a discounted forward PE implying strong earnings growth, and the post-pandemic rebound in its core service verticals. The bearish case hinges on the company's precarious financial health, characterized by extremely thin margins, high leverage, and tight liquidity. Currently, the technical momentum and forward-looking valuation suggest the bulls have stronger near-term evidence, as the price action reflects high conviction in the recovery story. However, the single most important tension in the investment debate is whether ARMK's projected earnings growth of $3.88 EPS can materialize and be sustained, given its razor-thin 1.76% net margin and leveraged balance sheet. If inflation or a downturn pressures those margins, the forward PE multiple of 20.2x could quickly prove unjustified.
Bullish
- Powerful Technical Momentum: ARMK has surged 45.0% over the past six months and 35.7% over three months, dramatically outperforming the S&P 500's 8.8% and 12.0% returns. The stock is trading at 98.7% of its 52-week high ($54.92), signaling strong bullish conviction and potential for a breakout.
- Strong Forward Earnings Growth: Analysts project forward EPS of $3.88, implying a significant earnings recovery. This is reflected in the valuation gap between a trailing PE of 31.5x and a forward PE of 20.2x, suggesting the market is pricing in robust profit growth over the next year.
- Attractive Relative Valuation Metrics: The stock trades at a Price-to-Sales ratio of 0.56x and an EV/Sales of 1.05x, which appear low for a market leader. The PEG ratio of 1.31 suggests the forward PE of 20.2x is reasonable relative to expected growth, indicating potential value.
- Post-Pandemic Recovery Narrative: The company's core verticals—sports, entertainment, education, and healthcare—are experiencing a strong post-pandemic rebound. This recovery is a key driver of the stock's 34.6% one-year price appreciation and underpins analyst optimism.
Bearish
- Extremely Thin Operating Margins: ARMK operates on razor-thin margins, with a gross margin of 5.78% and a net margin of 1.76%. This leaves minimal room for error in managing inflationary cost pressures or competitive pricing, directly threatening profitability.
- Highly Leveraged Balance Sheet: The company's debt-to-equity ratio is elevated at 1.82, indicating significant financial leverage. Coupled with a current ratio of 0.99, which signals potential liquidity constraints, this increases financial risk, especially in a rising rate environment.
- Technically Overextended Near Resistance: Trading at $54.27, just below the 52-week high of $54.92, the stock is in a state of extreme momentum. With a beta of 1.19, this parabolic 45% six-month move increases the risk of a sharp technical pullback or consolidation if it fails to break through resistance.
- Limited Analyst Coverage & Visibility: Only 5 analysts cover the stock, leading to less efficient price discovery and higher potential volatility. The lack of explicit price targets or consensus ratings makes it difficult to gauge institutional sentiment and anchor a fair value estimate.
ARMK Technical Analysis
The stock is in a powerful, sustained uptrend, with a 1-year price change of +34.60% and a 6-month surge of +45.03%. As of the latest close at $54.27, the price is trading at approximately 98.7% of its 52-week high of $54.92, indicating it is testing a major resistance level and is in a state of extreme momentum, which could signal either a pending breakout or a potential for a near-term pullback due to overextension. Recent short-term momentum is exceptionally strong, with a 1-month gain of +6.94% and a 3-month surge of +35.68%, both significantly outpacing the S&P 500's returns of -0.08% and +12.0% over the same periods, respectively; this divergence from the broader market and acceleration from the longer-term trend underscores intense, stock-specific bullish sentiment. Key technical levels are the immediate resistance at the 52-week high of $54.92 and support near the 52-week low of $35.07; a confirmed breakout above $54.92 would signal a continuation of the powerful uptrend, while a failure could lead to consolidation. With a beta of 1.19, the stock exhibits roughly 19% more volatility than the market, which is a relevant consideration for risk management given its recent parabolic move.
Beta
1.19
1.19x market volatility
Max Drawdown
-18.4%
Largest decline past year
52-Week Range
$35-$56
Price range past year
Annual Return
+33.8%
Cumulative gain past year
| Period | ARMK Return | S&P 500 |
|---|---|---|
| 1m | +5.1% | -2.9% |
| 3m | +40.7% | +15.0% |
| 6m | +49.8% | +5.6% |
| 1y | +33.8% | +19.1% |
| ytd | +53.3% | +6.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ARMK Fundamental Analysis
Data not available for a detailed analysis of revenue trajectory, profitability margins, and balance sheet health. The provided key metrics show a trailing net margin of 1.76% and a gross margin of 5.78%, indicating the company operates on very thin margins typical of the low-margin food service industry. The debt-to-equity ratio is elevated at 1.82, suggesting a leveraged balance sheet, while the current ratio of 0.99 points to potential liquidity constraints in covering short-term obligations. Analyst estimates for the forward period project revenue of approximately $27.28 billion and EPS of $3.88, but without historical quarterly financials, cash flow statements, or segment data, a comprehensive assessment of growth drivers, margin trends, and cash generation capability cannot be performed.
Quarterly Revenue
N/A
N/A
Revenue YoY Growth
N/A
YoY Comparison
Gross Margin
N/A
Latest Quarter
Free Cash Flow
N/A
Last 12 Months
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ARMK Overvalued?
Given the company is profitable with a positive net margin, the primary valuation metric is the Price-to-Earnings (PE) ratio. The trailing PE is 31.53x, while the forward PE is significantly lower at 20.22x; this substantial gap implies the market is pricing in a robust recovery in earnings over the next twelve months, aligning with analyst EPS estimates of $3.88. Compared to sector averages, the stock's Price-to-Sales (PS) ratio of 0.56x and EV/Sales of 1.05x appear low, but without specific industry average data provided, a precise premium/discount calculation is not possible; the forward PE of 20.2x seems reasonable for a company in recovery if it can deliver on projected earnings growth, as suggested by a PEG ratio of 1.31. Historical context for valuation is unavailable due to missing historical ratios data, preventing an analysis of whether the current multiples are at the high or low end of the stock's own historical range, which is a critical blind spot in assessing if optimistic expectations are already fully priced in.
PE
31.5x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
12.3x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: ARMK's primary risks stem from its fragile financial structure. The company operates with exceptionally thin margins—a 1.76% net margin and 5.78% gross margin—leaving it highly vulnerable to inflationary cost shocks in food and labor, which could erase profits. Its balance sheet is heavily leveraged, with a debt-to-equity ratio of 1.82, increasing interest expense sensitivity in a higher-rate environment. Furthermore, a current ratio of 0.99 indicates it has barely enough liquid assets to cover short-term liabilities, posing a liquidity risk if operations face a sudden downturn.
Market & Competitive Risks: Externally, the stock faces valuation compression risk after its parabolic 45% six-month surge. Trading near 52-week highs, any disappointment in forward earnings could trigger a sharp multiple contraction from its current forward PE of 20.2x. Its beta of 1.19 means it is 19% more volatile than the market, amplifying downside moves during broader sell-offs. Recent news highlighting persistent inflation and delayed Fed rate cuts poses a macro headwind, potentially pressuring consumer-facing businesses and increasing its clients' cost-consciousness, which could impact contract renewals and pricing power.
Worst-Case Scenario: The most damaging scenario would involve a combination of a margin-squeezing inflationary spike and a broader economic slowdown. This could lead to a significant earnings miss versus the $3.88 EPS estimate, triggering analyst downgrades and a rapid derating of the forward PE multiple. Coupled with its high beta, this could precipitate a sharp sell-off towards its 52-week low of $35.07. From the current price of $54.27, this represents a potential downside of approximately -35%. Such a move would also be consistent with its historical maximum drawdown of -18.37%, which could be exceeded in a severe adverse scenario.
FAQ
The key risks are, in order of severity: 1) Financial Risk: High leverage (Debt/Equity 1.82) and tight liquidity (Current Ratio 0.99) make the company vulnerable to rising rates or a downturn. 2) Operational Risk: Extremely thin gross (5.78%) and net (1.76%) margins offer no buffer against inflation. 3) Valuation Risk: The stock is trading at 98.7% of its 52-week high after a parabolic move, increasing the chance of a sharp pullback (Beta: 1.19). 4) Coverage Risk: Limited analyst coverage (5 analysts) can lead to higher volatility and inefficient price discovery.
The 12-month forecast presents three scenarios. The Base Case (55% probability) sees the stock trading between $50 and $56 as it meets analyst EPS estimates of $3.88 and consolidates its recent gains. The Bull Case (25% probability) targets $57 to $62 on an earnings beat and successful breakout above resistance. The Bear Case (20% probability) warns of a drop to $35-$45 if margins compress and earnings disappoint. The Base Case is most likely, hinging on the assumption that ARMK delivers on its current earnings projections without major setbacks.
ARMK's valuation sends mixed signals. Its forward PE of 20.2x is reasonable relative to expected growth (PEG: 1.31), and its Price-to-Sales ratio of 0.56x appears low. However, the trailing PE of 31.5x indicates the market is pricing in a significant earnings jump. Compared to its own fundamentals—particularly the thin margins and high leverage—the stock appears fairly valued to slightly overvalued after its massive rally. The valuation implies the market expects a flawless execution of the earnings recovery story, leaving little room for error.
ARMK is a speculative buy only for risk-tolerant investors who believe the post-pandemic earnings recovery will exceed expectations. The stock has already surged 45% in six months, pricing in much of the optimism, and trades at a forward PE of 20.2x based on projected EPS of $3.88. The biggest downside risk is its leveraged balance sheet (Debt/Equity: 1.82) and razor-thin 1.76% net margin, which could lead to significant losses if growth stalls. It is not a good buy for conservative investors seeking stability or margin of safety.
ARMK is more suitable for a medium-term investment horizon of 12-24 months, aligning with the timeline of its post-pandemic recovery narrative. Its high beta (1.19) and recent parabolic move make it risky for short-term trading, as it is prone to sharp swings. The low dividend yield (1.08%) does not support a long-term income strategy. Given the cyclical nature of its business and leveraged balance sheet, investors should be prepared to monitor quarterly results closely and have an exit strategy. A minimum holding period of one year is suggested to allow the earnings story to play out.